Do analysts recommend XTLB or ESLA?

Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 1,563.20%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, XTLB or ESLA?

XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XTL Biopharmaceuticals N/A N/A -$6.97M -$0.64 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.24 N/A

Is XTLB or ESLA more profitable?

Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Estrella Immunopharma N/A N/A -328.72%

Do analysts prefer XTLB or JSPR?

Jasper Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,103.96%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jasper Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29

Which has stronger valuation & earnings, XTLB or JSPR?

XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XTL Biopharmaceuticals N/A N/A -$6.97M -$0.64 N/A Jasper Therapeutics N/A N/A -$75.80M -$1.59 N/A

Is XTLB or JSPR more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Jasper Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Jasper Therapeutics N/A -884.17% -143.83%

Do analysts prefer MRKR or XTLB?

Marker Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 769.57%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Marker Therapeutics is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, MRKR or XTLB?

XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Marker Therapeutics N/A N/A -$12.16M -$0.41 N/A XTL Biopharmaceuticals N/A N/A -$6.97M -$0.64 N/A

Does the media favor MRKR or XTLB?

In the previous week, Marker Therapeutics had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for Marker Therapeutics and 3 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.94 beat Marker Therapeutics' score of 0.40 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate XTLB or NEUP?

Neuphoria Therapeutics has a consensus target price of $7.00, indicating a potential upside of 92.31%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is XTLB or NEUP more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Neuphoria Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Neuphoria Therapeutics N/A -38.31% -28.92%

Does the media prefer XTLB or NEUP?

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for Neuphoria Therapeutics and 3 mentions for XTL Biopharmaceuticals. Neuphoria Therapeutics' average media sentiment score of 0.95 beat XTL Biopharmaceuticals' score of 0.94 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neuphoria Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer XTLB or AKTX?

Akari Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 231.28%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has stronger valuation & earnings, XTLB or AKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XTL Biopharmaceuticals N/A N/A -$6.97M -$0.64 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is XTLB or AKTX more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Akari Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Akari Therapeutics N/A -147.45% -74.70%

Does the media refer more to XTLB or AKTX?

In the previous week, XTL Biopharmaceuticals and XTL Biopharmaceuticals both had 3 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 0.94 equaled Akari Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akari Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

XTL Biopharmaceuticals (XTLB) Competitors

$2.29 -0.12 (-5.15%)

Closing price 09/25/2026 03:55 PM Eastern

Extended Trading

$2.26 -0.03 (-1.36%)

As of 09/25/2026 04:10 PM Eastern

Compare

XTLB vs. ESLA, JSPR, MRKR, NEUP, and AKTX

Should you buy XTL Biopharmaceuticals stock or one of its competitors? XTL Biopharmaceuticals's main competitors and comparable companies include Estrella Immunopharma (ESLA), Jasper Therapeutics (JSPR), Marker Therapeutics (MRKR), Neuphoria Therapeutics (NEUP), and Akari Therapeutics (AKTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does XTL Biopharmaceuticals compare to Estrella Immunopharma?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Estrella Immunopharma	N/A	N/A	-328.72%

XTL Biopharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 1,563.20%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	N/A	N/A	-$6.97M	-$0.64	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

In the previous week, XTL Biopharmaceuticals had 2 more articles in the media than Estrella Immunopharma. MarketBeat recorded 3 mentions for XTL Biopharmaceuticals and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 1.79 beat XTL Biopharmaceuticals' score of 0.94 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Positive
Estrella Immunopharma	Very Positive

Summary

XTL Biopharmaceuticals and Estrella Immunopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Jasper Therapeutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	N/A	N/A	-$6.97M	-$0.64	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$1.59	N/A

In the previous week, XTL Biopharmaceuticals had 2 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for XTL Biopharmaceuticals and 1 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 1.06 beat XTL Biopharmaceuticals' score of 0.94 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Positive
Jasper Therapeutics	Positive

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 3.9% of Jasper Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

XTL Biopharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3.04, suggesting that its stock price is 204% more volatile than the broader market.

Jasper Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,103.96%. Given Jasper Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jasper Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

XTL Biopharmaceuticals' return on equity of 0.00% beat Jasper Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Jasper Therapeutics	N/A	-884.17%	-143.83%

Summary

Jasper Therapeutics beats XTL Biopharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Marker Therapeutics currently has a consensus price target of $10.00, indicating a potential upside of 769.57%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Marker Therapeutics is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	N/A	N/A	-$12.16M	-$0.41	N/A
XTL Biopharmaceuticals	N/A	N/A	-$6.97M	-$0.64	N/A

Marker Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

XTL Biopharmaceuticals has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. XTL Biopharmaceuticals' return on equity of 0.00% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-56.96%	-47.82%
XTL Biopharmaceuticals	N/A	N/A	N/A

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Marker Therapeutics had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for Marker Therapeutics and 3 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.94 beat Marker Therapeutics' score of 0.40 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Marker Therapeutics beats XTL Biopharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Neuphoria Therapeutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Neuphoria Therapeutics has a consensus target price of $7.00, indicating a potential upside of 92.31%. Given Neuphoria Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neuphoria Therapeutics is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

XTL Biopharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

XTL Biopharmaceuticals has higher earnings, but lower revenue than Neuphoria Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	N/A	N/A	-$6.97M	-$0.64	N/A
Neuphoria Therapeutics	$1.17M	16.77	-$13.45M	-$6.22	N/A

XTL Biopharmaceuticals' return on equity of 0.00% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Neuphoria Therapeutics	N/A	-38.31%	-28.92%

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for Neuphoria Therapeutics and 3 mentions for XTL Biopharmaceuticals. Neuphoria Therapeutics' average media sentiment score of 0.95 beat XTL Biopharmaceuticals' score of 0.94 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neuphoria Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neuphoria Therapeutics beats XTL Biopharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Akari Therapeutics?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Akari Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 231.28%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	N/A	N/A	-$6.97M	-$0.64	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

XTL Biopharmaceuticals' return on equity of 0.00% beat Akari Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Akari Therapeutics	N/A	-147.45%	-74.70%

In the previous week, XTL Biopharmaceuticals and XTL Biopharmaceuticals both had 3 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 0.94 equaled Akari Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akari Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XTL Biopharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

Summary

Akari Therapeutics beats XTL Biopharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get XTL Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XTLB vs. The Competition

Export

Metric	XTL Biopharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.21M	$3.94B	$7.33B	$13.17B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-3.57	14.15	275.82	25.78
Price / Sales	N/A	1,438.70	649.60	92.85
Price / Cash	N/A	120.91	79.52	52.89
Price / Book	-20.78	15.28	10.44	6.30
Net Income	-$6.97M	-$22.90M	$3.51B	$360.35M
7 Day Performance	0.70%	-2.94%	-1.31%	-0.23%
1 Month Performance	-11.40%	-8.80%	-4.61%	-4.16%
1 Year Performance	N/A	28.99%	15.01%	4.58%

XTL Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XTLB XTL Biopharmaceuticals	0.8856 of 5 stars	$2.29 -5.1%	N/A	N/A	$5.21M	N/A	N/A	10	News Coverage Positive News Short Interest Decrease
ESLA Estrella Immunopharma	1.6967 of 5 stars	$0.47 -2.7%	$8.00 +1,594.9%	-59.9%	$21.10M	N/A	N/A	N/A	Analyst Upgrade
JSPR Jasper Therapeutics	1.958 of 5 stars	$0.57 -9.0%	$7.33 +1,193.8%	-75.3%	$20.73M	N/A	N/A	22	News Coverage Positive News
MRKR Marker Therapeutics	2.2136 of 5 stars	$1.24 +1.6%	$10.00 +706.5%	+21.1%	$20.34M	N/A	N/A	60	Short Interest Increase
NEUP Neuphoria Therapeutics	2.778 of 5 stars	$3.68 -1.3%	$7.00 +90.2%	-70.4%	$20.21M	$1.17M	N/A	8	News Coverage Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XTLB) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. ESLA, JSPR, MRKR, NEUP, and AKTX

How does XTL Biopharmaceuticals compare to Estrella Immunopharma?

Summary

How does XTL Biopharmaceuticals compare to Jasper Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to Marker Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to Neuphoria Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to Akari Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. ESLA, JSPR, MRKR, NEUP, and AKTX

How does XTL Biopharmaceuticals compare to Estrella Immunopharma?

Is XTLB or ESLA more profitable?

Which has more volatility and risk, XTLB or ESLA?

Do analysts recommend XTLB or ESLA?

Do insiders and institutionals believe in XTLB or ESLA?

Which has higher earnings and valuation, XTLB or ESLA?

Does the media prefer XTLB or ESLA?

Summary

How does XTL Biopharmaceuticals compare to Jasper Therapeutics?

Which has stronger valuation & earnings, XTLB or JSPR?

Does the media prefer XTLB or JSPR?

Do insiders & institutionals hold more shares of XTLB or JSPR?

Which has more volatility & risk, XTLB or JSPR?

Do analysts prefer XTLB or JSPR?

Is XTLB or JSPR more profitable?

Summary

How does XTL Biopharmaceuticals compare to Marker Therapeutics?

Do analysts prefer MRKR or XTLB?

Which has better earnings & valuation, MRKR or XTLB?

Which has more volatility and risk, MRKR or XTLB?

Is MRKR or XTLB more profitable?

Do institutionals & insiders believe in MRKR or XTLB?

Does the media favor MRKR or XTLB?

Summary

How does XTL Biopharmaceuticals compare to Neuphoria Therapeutics?

Do insiders and institutionals have more ownership in XTLB or NEUP?

Do analysts rate XTLB or NEUP?

Which has more volatility & risk, XTLB or NEUP?

Which has better valuation and earnings, XTLB or NEUP?

Is XTLB or NEUP more profitable?

Does the media prefer XTLB or NEUP?

Summary

How does XTL Biopharmaceuticals compare to Akari Therapeutics?

Do analysts prefer XTLB or AKTX?

Do institutionals & insiders hold more shares of XTLB or AKTX?

Which has stronger valuation & earnings, XTLB or AKTX?

Is XTLB or AKTX more profitable?

Does the media refer more to XTLB or AKTX?

Which has more volatility and risk, XTLB or AKTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools